Group One Trading, L.P. Relmada Therapeutics, Inc. Transaction History

Group One Trading, L.P.

$3.01 Billion
Q2 2024

A detailed history of Group One Trading, L.P. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 148,927 shares of RLMD stock, worth $506,351. This represents 0.01% of its overall portfolio holdings.

Number of Shares

148,927

Previous 184,338 19.21%

Holding current value

$506,351

Previous $857,000 47.96%

% of portfolio

0.01%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $103,754 - $174,930	-35,411 Reduced 19.21%	148,927 $446,000
Q1 2024 May 10, 2024	BUY	$3.1 - $6.8 $80,324 - $176,194	25,911 Added 16.36%	184,338 $857,000
Q4 2023 Feb 14, 2024	SELL	$2.45 - $4.22 $5,086 - $8,760	-2,076 Reduced 1.29%	158,427 $655,000
Q3 2023 Nov 09, 2023	BUY	$2.48 - $3.79 $59,391 - $90,762	23,948 Added 17.54%	160,503 $481,000
Q2 2023 Aug 09, 2023	BUY	$2.22 - $3.54 $206,151 - $328,727	92,861 Added 212.53%	136,555 $335,000
Q1 2023 May 12, 2023	SELL	$2.24 - $4.76 $223,643 - $475,243	-99,841 Reduced 69.56%	43,694 $98,000
Q4 2022 Feb 09, 2023	BUY	$2.17 - $35.84 $311,470 - $5.14 Million	143,535 New	143,535 $500,000
Q2 2022 Aug 11, 2022	BUY	$16.5 - $30.34 $55,341 - $101,760	3,354 New	3,354 $64,000
Q4 2021 Feb 11, 2022	SELL	$16.93 - $26.82 $34,452 - $54,578	-2,035 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$21.86 - $34.77 $113,344 - $180,282	-5,185 Reduced 71.81%	2,035 $53,000
Q2 2021 Aug 10, 2021	BUY	$29.55 - $39.15 $29,550 - $39,150	1,000 Added 16.08%	7,220 $231,000
Q1 2021 May 12, 2021	BUY	$31.52 - $39.28 $196,054 - $244,321	6,220 New	6,220 $219,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

13.5M

Call Options Held

99K

Put Options Held

28.2K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $97.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account

Group One Trading, L.P. Relmada Therapeutics, Inc. Transaction History